Compare Novartis AG (NVS) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Xpeng Inc - ADR — how do they compare? Novartis AG trades at $143.2 (market cap $268.57B), while Xpeng Inc - ADR trades at $9.97 (market cap $9.16B). The key difference: Novartis AG is far larger — about 29.3× Xpeng Inc - ADR's market cap, and Novartis AG pays a 3.31% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Novartis AG for 82 Days and Xpeng Inc - ADR for 80 Days on average.
| NVS | XPEV | |
|---|---|---|
Market Cap | $268.57B | $9.16B |
Volume | 1,532,573 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $28.07 |
52-Week Low | $121.80 | $9.25 |
Typical Hold Time | 82 Days | 80 Days |
Enterprise Value | $309.89B | $11.09B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
XPeng (XPEV) trades at $9.58, up 0.21% today, with a bearish technical signal despite oversold RSI readings. The company reported strong Q4 2025 earnings beat but missed Q1 and Q2 2026 expectations. Revenue grew to $76.72B in 2025, with net losses narrowing to -$1.14B. Recent news highlights XPeng's expansion into humanoid robotics and global vehicle launches, including the G9L SUV debut at the Paris Motor Show.
XPeng shows improving revenue growth and narrowing losses, but persistent unprofitability and high EV/EBITDA of 144.25 pose valuation concerns. Analyst consensus is bullish with a $17.55 price target, though execution risks in new robotics ventures and competitive EV market pressures remain key challenges for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
